8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 10, 2026·SEC
Sutro Biopharma, Inc.(STRO)Earnings, Financials & Key Ratios
STRO•NASDAQ
Price updated Jun 19, 2026
AboutSutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Show more
- Revenue$102M+65.2%
- EBITDA-$98M+57.8%
- Net Income-$191M+16.0%
- EPS (Diluted)-22.49+24.0%
- Gross Margin92.85%+5.1%
- EBITDA Margin-95.26%+74.4%
- Operating Margin-102.41%+73.4%
- Net Margin-186.45%+49.1%
STRO Key Insights
Sutro Biopharma, Inc. (STRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Strong 5Y sales CAGR of 19.1%
✗Weaknesses
- ✗Profits declining 42.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when STRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STRO Price & Volume
Sutro Biopharma, Inc. (STRO) stock price & volume — 10-year historical chart
Loading chart...
STRO Growth Metrics
Sutro Biopharma, Inc. (STRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.12%
3 Years14.78%
TTM49.94%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM37.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.48%
Return on Capital
10 Years-46.35%
5 Years-45.91%
3 Years-53.2%
Last Year-59.29%
STRO Recent Earnings
Sutro Biopharma, Inc. (STRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$2.94-26.7%
$2.32
Rev
$15M+63.3%
$9M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$5.29-13.5%
$4.66
Rev
$12M+25.8%
$9M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$5.29+35.2%
$8.16
Rev
$12M+25.8%
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$6.70-59.5%
$4.20
Rev
$10M-4.4%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.94vs $2.32-26.7% | $15Mvs $9M+63.3% |
| Q2 2026 | Mar 26, 2026 | $5.29vs $4.66-13.5% | $12Mvs $9M+25.8% |
| Q2 2026 | Mar 23, 2026 | $5.29vs $8.16+35.2% | $12Mvs $9M+25.8% |
| Q4 2025 | Nov 6, 2025 | $6.70vs $4.20-59.5% | $10Mvs $10M-4.4% |
Based on last 12 quarters of dataView full earnings history →
STRO Peer Comparison
Sutro Biopharma, Inc. (STRO) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 BOLT | 7.67M | 3.99 | -0.22 | 0.07% | -455.15% | -100.9% | 0.87 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 PBYI | 384.8M | 7.56 | 12.39 | -0.91% | 10.73% | 20.37% | 0.22 |
Compare STRO vs Peers
Sutro Biopharma, Inc. (STRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STRO Income Statement
Sutro Biopharma, Inc. (STRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 51.74M | 38.42M | 42.74M | 42.72M | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M | 99.61M |
Revenue Growth % | -13.38% | -25.75% | 11.24% | -0.03% | 44.84% | 9.52% | 126.84% | -59.64% | 65.18% | 49.94% |
Cost of Goods Sold | 51.9M | 54.26M | 0 | 76.96M | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M | 1.28M |
COGS % of Revenue | 100.3% | 141.24% | - | 180.14% | 15.79% | 12.23% | 4.43% | 11.63% | 7.15% | - |
Gross Profit | -156K▲ 0% | -15.84M▼ 10055.8% | 42.74M▲ 369.7% | -34.24M▼ 180.1% | 52.11M▲ 252.2% | 59.48M▲ 14.2% | 146.91M▲ 147.0% | 54.83M▼ 62.7% | 95.16M▲ 73.6% | 98.33M▲ 0% |
Gross Margin % | -0.3% | -41.24% | 100% | -80.14% | 84.21% | 87.77% | 95.57% | 88.37% | 92.85% | 98.72% |
Gross Profit Growth % | -100.96% | -10055.77% | 369.75% | -180.12% | 252.19% | 14.16% | 146.98% | -62.68% | 73.57% | - |
Operating Expenses | 71.01M | 75.64M | 98.2M | 36.82M | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M | 213.41M |
OpEx % of Revenue | 137.25% | 196.89% | 229.79% | 86.18% | 243.42% | 278.03% | 153.64% | 472.7% | 195.26% | - |
Selling, General & Admin | 16.37M | 21.38M | 32.59M | 36.82M | 56M | 59.54M | 62.58M | 48.45M | 41.02M | 35.33M |
SG&A % of Revenue | 31.65% | 55.65% | 76.26% | 86.18% | 90.5% | 87.86% | 40.71% | 78.1% | 40.02% | - |
Research & Development | 54.64M | 54.26M | 65.61M | 76.96M | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M | 151.37M |
R&D % of Revenue | 105.6% | 141.24% | 153.53% | 180.14% | 168.71% | 202.4% | 117.36% | 406.24% | 162.38% | - |
Other Operating Expenses | -77K | 1.91M | 0 | -76.96M | -9.77M | -8.29M | -6.82M | -7.22M | -7.32M | 1000K |
Operating Income | -19.27M▲ 0% | -37.22M▼ 93.1% | -55.47M▼ 49.0% | -71.06M▼ 28.1% | -98.52M▼ 38.7% | -128.94M▼ 30.9% | -89.28M▲ 30.8% | -238.45M▼ 167.1% | -104.95M▲ 56.0% | -115.08M▲ 0% |
Operating Margin % | -37.25% | -96.89% | -129.79% | -166.32% | -159.22% | -190.26% | -58.07% | -384.34% | -102.41% | -115.53% |
Operating Income Growth % | -1512.9% | -93.15% | -49.02% | -28.1% | -38.65% | -30.87% | 30.76% | -167.09% | 55.99% | - |
EBITDA | -14.28M | -32.68M | -50.69M | -66.76M | -93.68M | -120.66M | -82.46M | -231.24M | -97.63M | -108.37M |
EBITDA Margin % | -27.6% | -85.07% | -118.61% | -156.27% | -151.39% | -178.03% | -53.64% | -372.7% | -95.26% | -108.8% |
EBITDA Growth % | -303.27% | -128.85% | -55.09% | -31.7% | -40.32% | -28.79% | 31.65% | -180.41% | 57.78% | 55.41% |
D&A (Non-Cash Add-back) | 4.99M | 4.54M | 4.78M | 4.3M | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M | 6.7M |
EBIT | -19.08M | -37.22M | -51.39M | -28.05M | -102.4M | -113.36M | -74.73M | -187.67M | -104.95M | -113.41M |
Net Interest Income | -416K | 16K | -276K | -2.47M | -2.56M | 109K | -9.24M | 13.36M | -28.96M | -32.15M |
Interest Income | 273K | 1.62M | 4.07M | 1.51M | 577K | 3.46M | 14.51M | 44.42M | 9.25M | 7.7M |
Interest Expense | 689K | 1.6M | 4.35M | 3.97M | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M | 39.85M |
Other Income/Expense | -416K | 1.91M | -276K | 38.93M | -7.01M | 12.24M | 677K | 13.36M | -86.23M | -38.64M |
Pretax Income | -19.69M▲ 0% | -35.32M▼ 79.4% | -55.74M▼ 57.8% | -32.13M▲ 42.4% | -105.54M▼ 228.5% | -116.7M▼ 10.6% | -88.6M▲ 24.1% | -225.1M▼ 154.1% | -191.18M▲ 15.1% | -153.72M▲ 0% |
Pretax Margin % | -38.05% | -91.93% | -130.44% | -75.2% | -170.55% | -172.2% | -57.63% | -362.81% | -186.55% | -154.32% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 2.5M | 18.19M | 2.36M | -93K | -115K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -2.14% | -20.53% | -1.05% | 0.05% | 0.07% |
Net Income | -19.69M▲ 0% | -35.32M▼ 79.4% | -55.74M▼ 57.8% | -32.13M▲ 42.4% | -105.54M▼ 228.5% | -119.2M▼ 12.9% | -106.79M▲ 10.4% | -227.46M▼ 113.0% | -191.09M▲ 16.0% | -153.6M▲ 0% |
Net Margin % | -38.05% | -91.93% | -130.44% | -75.2% | -170.55% | -175.89% | -69.47% | -366.62% | -186.45% | -154.21% |
Net Income Growth % | -1256.76% | -79.38% | -57.84% | 42.37% | -228.49% | -12.95% | 10.41% | -112.99% | 15.99% | 37.36% |
Net Income (Continuing) | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M | -227.46M | -191.09M | -153.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -28.10▲ 0% | -15.40▲ 45.2% | -24.30▼ 57.8% | -9.90▲ 59.3% | -22.90▼ 131.3% | -23.50▼ 2.6% | -17.80▲ 24.3% | -29.60▼ 66.3% | -22.49▲ 24.0% | -11.74▲ 0% |
EPS Growth % | -172.8% | 45.2% | -57.79% | 59.26% | -131.31% | -2.62% | 24.26% | -66.29% | 24.02% | 44.48% |
EPS (Basic) | -28.10 | -15.50 | -24.30 | -9.90 | -22.90 | -23.50 | -17.80 | -29.60 | -22.49 | - |
Diluted Shares Outstanding | 699.74K | 2.29M | 2.3M | 3.26M | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M | 13.08M |
Basic Shares Outstanding | 699.74K | 2.29M | 2.3M | 3.26M | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M | 13.08M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
STRO Balance Sheet
Sutro Biopharma, Inc. (STRO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.63M | 209.95M | 128.57M | 378.18M | 218.51M | 353.15M | 421.54M | 343.31M | 150.93M | 220.97M |
Cash & Short-Term Investments | 22.02M | 204.49M | 117.86M | 368.14M | 197.94M | 334.36M | 375.62M | 316.89M | 141.43M | 202.56M |
Cash Only | 22.02M | 125.3M | 4.96M | 206.15M | 30.41M | 47.25M | 69.27M | 190.3M | 58.13M | 73.68M |
Short-Term Investments | 0 | 79.19M | 112.9M | 161.99M | 167.52M | 287.11M | 306.35M | 126.59M | 83.3M | 128.88M |
Accounts Receivable | 1.62M | 2.49M | 6.3M | 5.56M | 12.45M | 7.12M | 36.08M | 8.62M | 3.98M | 12.48M |
Days Sales Outstanding | 11.46 | 23.65 | 53.79 | 47.49 | 73.46 | 38.36 | 85.66 | 50.69 | 14.16 | 26 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 2.96M | 4.41M | 0 | 0 | 11.67M | 9.85M | 17.8M | 5.52M | 5.93M |
Total Non-Current Assets | 15.14M | 13.19M | 27.8M | 15.93M | 122.89M | 53.79M | 49.19M | 43.9M | 22.9M | 21.02M |
Property, Plant & Equipment | 14M | 10.93M | 9.63M | 12.94M | 51.59M | 51.06M | 44.76M | 35.87M | 21.55M | 19.07M |
Fixed Asset Turnover | 3.70x | 3.51x | 4.44x | 3.30x | 1.20x | 1.33x | 3.43x | 1.73x | 4.76x | 4.10x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 223K | 15K | 15.62M | 0 | 68.78M | -32.02M | 0 | 0 | 0 | 1.72M |
Other Non-Current Assets | 920K | 2.24M | 2.54M | 2.99M | 2.53M | 34.75M | 4.44M | 8.03M | 1.35M | 1.95M |
Total Assets | 40.77M▲ 0% | 223.14M▲ 447.3% | 156.37M▼ 29.9% | 394.11M▲ 152.0% | 341.41M▼ 13.4% | 406.94M▲ 19.2% | 470.74M▲ 15.7% | 387.21M▼ 17.7% | 173.83M▼ 55.1% | 241.99M▲ 0% |
Asset Turnover | 1.27x | 0.17x | 0.27x | 0.11x | 0.18x | 0.17x | 0.33x | 0.16x | 0.59x | 0.45x |
Asset Growth % | -41.15% | 447.33% | -29.92% | 152.04% | -13.37% | 19.2% | 15.68% | -17.74% | -55.11% | -179.77% |
Total Current Liabilities | 31.96M | 36.42M | 32.97M | 29.6M | 41.74M | 66.55M | 93.75M | 131.89M | 75.13M | 70.81M |
Accounts Payable | 2.9M | 3.06M | 5.58M | 5.54M | 6.01M | 4.8M | 9.44M | 10.47M | 7.57M | 5.49M |
Days Payables Outstanding | 20.41 | 20.59 | - | 26.29 | 224.42 | 211.26 | 505.52 | 529.7 | 377.01 | 1.74K |
Short-Term Debt | 14.56M | 4.72M | 1M | 0 | 9.38M | 17.09M | 4.06M | 0 | 7.78M | 7.6M |
Deferred Revenue (Current) | 10.71M | 21.57M | 19.46M | 14.6M | 5.5M | 16.76M | 20.67M | 69.78M | 10.56M | 40.9M |
Other Current Liabilities | 143K | 7.06M | 901K | 627K | 11.42M | 11.64M | 18.58M | 16.91M | 49.22M | 48.33M |
Current Ratio | 0.80x | 5.76x | 3.90x | 12.78x | 5.24x | 5.31x | 4.50x | 2.60x | 2.01x | 3.12x |
Quick Ratio | 0.80x | 5.76x | 3.90x | 12.78x | 5.24x | 5.31x | 4.50x | 2.60x | 2.01x | 3.12x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.72K |
Total Non-Current Liabilities | 117.81M | 55.18M | 25.61M | 32.47M | 47.11M | 123.35M | 227.34M | 210.71M | 231.15M | 238.06M |
Long-Term Debt | 0 | 10M | 8.88M | 24.55M | 15.74M | 3.77M | 0 | 0 | 7.89M | 6.03M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 31.22M | 29.57M | 23.15M | 15.67M | 0 | 19.43M |
Deferred Tax Liabilities | 0 | 476K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 104.66M | 578K | 543K | 1.82M | 146K | 119K | 1.69M | 1.69M | 223.26M | 232.03M |
Total Liabilities | 149.77M | 91.6M | 58.58M | 62.06M | 88.84M | 189.9M | 321.09M | 342.61M | 306.28M | 308.88M |
Total Debt | 14.63M | 14.72M | 9.88M | 24.55M | 57.37M | 55.02M | 33.63M | 23.15M | 15.67M | 13.63M |
Net Debt | -7.39M | -110.57M | 4.92M | -181.61M | 26.96M | 7.76M | -35.63M | -167.15M | -42.46M | -60.05M |
Debt / Equity | - | 0.11x | 0.10x | 0.07x | 0.23x | 0.25x | 0.22x | 0.52x | - | -0.20x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.13x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.55x |
Interest Coverage | -27.69x | -23.26x | -11.81x | -7.06x | -32.64x | -33.88x | -3.15x | -6.04x | -2.75x | -2.85x |
Total Equity | -109M▲ 0% | 131.54M▲ 220.7% | 97.79M▼ 25.7% | 332.05M▲ 239.6% | 252.56M▼ 23.9% | 217.05M▼ 14.1% | 149.65M▼ 31.1% | 44.6M▼ 70.2% | -132.45M▼ 397.0% | -66.89M▲ 0% |
Equity Growth % | -19.91% | 220.68% | -25.66% | 239.56% | -23.94% | -14.06% | -31.05% | -70.2% | -396.97% | -855.68% |
Book Value per Share | -155.77 | 57.53 | 42.59 | 101.94 | 54.76 | 42.78 | 24.87 | 5.81 | -15.59 | -5.11 |
Total Shareholders' Equity | -109M | 131.54M | 97.79M | 332.05M | 252.56M | 217.05M | 149.65M | 44.6M | -132.45M | -66.89M |
Common Stock | 0 | 23K | 23K | 46K | 46K | 58K | 61K | 83K | 9K | 17K |
Retained Earnings | -115.01M | -150.33M | -195.75M | -227.87M | -333.41M | -452.62M | -559.41M | -786.87M | -977.96M | -1.02B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -208K | -47K | 165K | 129K | -314K | -618K | 21K | 39K | 19K | -101K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STRO Cash Flow Statement
Sutro Biopharma, Inc. (STRO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -37.07M | 12.68M | -65.02M | -67.8M | -81.68M | 3.55M | -111.62M | -191.54M | -177.23M | -151.61M |
Operating CF Margin % | -71.65% | 33.01% | -152.15% | -158.71% | -132% | 5.24% | -72.6% | -308.72% | -172.94% | - |
Operating CF Growth % | -181.87% | 134.21% | -612.68% | -4.27% | -20.47% | 104.35% | -3245% | -71.61% | 7.47% | -431.31% |
Net Income | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M | -227.46M | -191.09M | -153.6M |
Depreciation & Amortization | 4.99M | 4.54M | 4.78M | 4.3M | 4.84M | 5.69M | 6.82M | 7.22M | 7.32M | 5.42M |
Stock-Based Compensation | 1.39M | 2.87M | 10.31M | 11.92M | 23.24M | 26.3M | 24.91M | 24.69M | 14.01M | 8.47M |
Deferred Taxes | 3M | -1.5M | -1.3M | -41.01M | 7.24M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 132K | -517K | 193K | 606K | 6.16M | -13.65M | -2.17M | -4.88M | 42.92M | 46.3M |
Working Capital Changes | -26.9M | 42.61M | -23.26M | -11.49M | -17.62M | 104.41M | -34.38M | 8.9M | -50.4M | -58.2M |
Change in Receivables | -1.05M | -865K | -3.81M | 739K | -6.89M | 5.34M | -28.96M | 27.46M | 4.64M | 1.08M |
Change in Inventory | -354K | -1.67M | -1.25M | -58K | -4.54M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -473K | 209K | 2.25M | -947K | 6.43M | -1.23M | 4.81M | 706K | -2.47M | -3.13M |
Cash from Investing | 32.6M | -80.19M | -51.13M | 604K | -97.31M | -35.02M | -3.92M | 218.51M | 45.01M | 16.01M |
Capital Expenditures | -3.32M | -1.56M | -3.48M | -7.13M | -15.32M | -7.86M | -4.32M | -3.1M | -1.7M | -532K |
CapEx % of Revenue | 6.41% | 4.05% | 8.15% | 16.69% | 24.76% | 11.59% | 2.81% | 4.99% | 1.65% | 0.53% |
Acquisitions | 0 | 0 | 47.65M | 0 | 0 | 28.74M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 80K | 80K | -47.65M | 89K | 9K | -28.73M | 0 | 0 | 0 | 0 |
Cash from Financing | 14.64M | 170.78M | -4.18M | 269.25M | 3.26M | 48.31M | 137.55M | 94.05M | 44K | 103.05M |
Debt Issued (Net) | 15M | 0 | -5M | 15M | 0 | -9.38M | -12.5M | -4.08M | 0 | 0 |
Equity Issued (Net) | 0 | 169.18M | 1.11M | 251.41M | -994K | 56.27M | 11.97M | 96.53M | 376K | 103.31M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -327K | 0 | -7K | 0 | 0 | 0 | 0 | -60K |
Other Financing | -362K | 1.61M | -297K | 2.83M | 4.25M | 1.42M | 138.08M | 1.61M | -332K | -252K |
Net Change in Cash | 10.17M▲ 0% | 103.28M▲ 915.8% | -120.34M▼ 216.5% | 202.05M▲ 267.9% | -175.74M▼ 187.0% | 16.84M▲ 109.6% | 22.01M▲ 30.7% | 121.02M▲ 449.8% | -132.17M▼ 209.2% | -32.55M▲ 0% |
Free Cash Flow | -40.39M▲ 0% | 11.13M▲ 127.5% | -68.5M▼ 715.7% | -74.93M▼ 9.4% | -97M▼ 29.5% | -4.31M▲ 95.6% | -115.93M▼ 2590.4% | -194.64M▼ 67.9% | -178.93M▲ 8.1% | -152.14M▲ 0% |
FCF Margin % | -78.06% | 28.96% | -160.3% | -175.39% | -156.76% | -6.36% | -75.41% | -313.71% | -174.59% | -152.74% |
FCF Growth % | -130.18% | 127.55% | -715.71% | -9.38% | -29.46% | 95.56% | -2590.44% | -67.89% | 8.07% | 23.36% |
FCF per Share | -57.72 | 4.87 | -29.84 | -23.00 | -21.03 | -0.85 | -19.27 | -25.33 | -21.06 | -11.63 |
FCF Conversion (FCF/Net Income) | 1.88x | -0.36x | 1.17x | 2.11x | 0.77x | -0.03x | 1.05x | 0.84x | 0.93x | 0.99x |
Interest Paid | 0 | 0 | 0 | 0 | 2.05M | 0 | 1.13M | 310K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 103K | 0 | 379K | 17.52M | 0 | 4K |
STRO Key Ratios
Sutro Biopharma, Inc. (STRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -313.4% | -48.62% | -14.95% | -36.11% | -50.77% | -58.25% | -234.19% | - | 192.77% |
Return on Invested Capital (ROIC) | - | - | -67.28% | -42.1% | -34.37% | -38.35% | -39.52% | - | - | 366.08% |
Gross Margin | -0.3% | -41.24% | 100% | -80.14% | 84.21% | 87.77% | 95.57% | 88.37% | 92.85% | 98.72% |
Net Margin | -38.05% | -91.93% | -130.44% | -75.2% | -170.55% | -175.89% | -69.47% | -366.62% | -186.45% | -154.21% |
Debt / Equity | - | 0.11x | 0.10x | 0.07x | 0.23x | 0.25x | 0.22x | 0.52x | - | -0.20x |
Interest Coverage | -27.69x | -23.26x | -11.81x | -7.06x | -32.64x | -33.88x | -3.15x | -6.04x | -2.75x | -2.85x |
FCF Conversion | 1.88x | -0.36x | 1.17x | 2.11x | 0.77x | -0.03x | 1.05x | 0.84x | 0.93x | 0.99x |
Revenue Growth | -13.38% | -25.75% | 11.24% | -0.03% | 44.84% | 9.52% | 126.84% | -59.64% | 65.18% | 49.94% |
Related:STRO Dividend History·STRO Revenue History·STRO Price History·STRO P/E History·STRO Financial Ratios·STRO Institutional Holders
STRO SEC Filings & Documents
Sutro Biopharma, Inc. (STRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
STRO Frequently Asked Questions
Sutro Biopharma, Inc. (STRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sutro Biopharma, Inc. (STRO) reported $99.6M in revenue for fiscal year 2025. This represents a 67% increase from $59.7M in 2016.
Sutro Biopharma, Inc. (STRO) grew revenue by 65.2% over the past year. This is strong growth.
Sutro Biopharma, Inc. (STRO) reported a net loss of $153.6M for fiscal year 2025.
Dividend & Returns
Sutro Biopharma, Inc. (STRO) had negative free cash flow of $152.1M in fiscal year 2025, likely due to heavy capital investments.